Skip to main content
AmigoFish

Establishing Potosi Virus as a Human Pathogen - Part 2

From Neurology® Podcast · · 13 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In the second episode of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about the risks of immunosuppression for autoimmune neurologic diseases and how to optimize the benefits of immunotherapies while minimizing the associated risks.

Read the related article in Neurology®.

Disclosures can be found at Neurology.org.

________________________________________________

Dr. Jose Merino: This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week.

Dr. Stacey Clardy: This is Stacey Clardy from the Salt Lake City VA, back with part two of our Bugs and Drugs in the B-cell Era Depletion podcast with Justin Abbatemarco. We're talking about things that have come to the forefront in terms of infections and how they present and how to prevent them in B-cell depleted patients, but also as it applies to folks with immunocompromise of all varieties. We discussed specifically the Potosi virus in part one, and here we're going to talk more broadly about common viruses that our patients encounter and how we address this, what we can do to prevent things, and cautions around making sure patients are vaccinated, but being careful with those live vaccines as well. I hope you enjoy. Justin, how do you approach, first of all, anti-CD20 dosing, or what can you do to mitigate the effects of any therapy? And how do you feel about the possible role of immune globulin treatment here?

Dr. Justin Abbatemarco: It's such a challenging scenario, and sometimes asking for some help with our colleagues, allergy and immunology is a big part of our practice here. And asking whether or not possibly supplementing with IVIG, if especially their IG levels are low, is something to at least think about. As you've talked about in the podcast many times, we should get all of the samples that we need, both in serum and CSF before initiating IVIG because it can cloud all of those results. And so saving those samples beforehand. And also again, acknowledging that there's not great data to help support this. Maybe the best data is within the West Nile literature that it's possible IVIG, especially if it's pooled around that area, might have relevant autoantibodies to help that patient fight off infection, and was published in some of the reports you've already mentioned. And to see if that would offer any chance, again, in these really challenging spots where we don't have effective vaccinations, we don't have effective antivirals, and how are we going to help patients? It's a multidisciplinary discussion. How do you think about it in your practice?

Dr. Stacey Clardy: The same, really. We're in autoimmuneology, so we're accustomed to having discussions where there isn't high-quality data. We all are equally frustrated by the fact that usually at best we can discuss low-quality case series, retrospective studies. And so I explain that whole concept of what I'm coming to the table with, to the family and to the patient, and say, "This is low-quality data. I want you to know that," so that they understand the level I'm presenting and the level they're making a decision with. Of course, yes, always preserving those samples and the ability to hopefully find out in the future more of what's going on. But when you're in the hospital, when you're ill, when you're decompensating, those specific patients, yeah, certainly we have for West Nile cases given intravenous immunoglobulin as part of supportive care, but full well acknowledging to everyone, the family, the patient if they're well enough, the teams, this is a bit of a Hail Mary, and it's theoretical, just hoping that particular donor pool might be able to offer some prior infectious exposure immunity to the patient that's receiving that. So yeah, pretty much the same as you, I would say. And you're…

Back to Neurology® Podcast · Report a problem